Keri Maher is an Oncology physician affiliated with Virginia Cancer Institute. OpenAlex indexes 120 publications with 249 citations (h-index 8); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1300 E Marshall St
Richmond, VA 232985028
Telephone
804-828-7999Provider last certified this registry record 25 Sept 2020.
Clinical trials
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
Sponsor: Virginia Commonwealth University
- Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Sponsor: Virginia Commonwealth University
- Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Sponsor: Virginia Commonwealth University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20259 payments$17,625openpaymentsdata.cms.gov ↗
- Rigel Pharmaceuticals, Inc.Program year20251 payment
- SOBI, INCProgram year202418 payments$38,260openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
28.3%Azole Antifungal14%Posaconazole52%Fluconazole24%Voriconazole24%Part D<11 patientsFluoroquinolone Antibacterial11.8%Levofloxacin100%Part D≥29 patients+ 1 more class in this area
Cancer & immunology
27.4%BCL-2 Inhibitor14%Venclexta100%Part D≥24 patientsKinase inhibitor6.2%Iclusig66%Gleevec34%Part D<11 patients+ 3 more classes in this area
Dermatology
23.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor23.9%Acyclovir100%Part D≥36 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2026–2026 per NIH RePORTER. The latest:
- Driving Transformation in NCI-sponsored Clinical Trials through Education, Leadership, and Community Partnership: An NCI-R50 Clinical-Scientist Award
Virginia Commonwealth University
FY2026$129,194R50CA318775 - Clinical Protocol and Data Management (CPDM)
Virginia Commonwealth University
FY2026$71,312P30CA016059
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Erin Alesi, MD
Virginia Cancer Institute
Lance Hampton, MD
Virginia Cancer Institute
Melissa Yacur, MD
Virginia Cancer Institute
Joshua McFarlane, MD
Virginia Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”